Emmanuelle Varon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emmanuelle Varon has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Corinne Levy
ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
12 shared publications - Robert Cohen
ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Saint Maur-des-Fossés, France
12 shared publications - Naïm Ouldali
Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France
7 shared publications - Stéphane Bonacorsi
Service de Microbiologie, Centre National de Référence Escherichia coli, AP-HP, Hôpital Robert-Debré, Université Paris-Cité, IAME, UMR 1137, INSERM, 75018 Paris, France
7 shared publications - Zein Assad
Université Paris Cité and Université Sorbonne Paris Nord, Inserm UMR 1137, IAME , Paris F-75018
5 shared publications - Alexis Rybak
Pediatric Emergency Department, Department of Woman Mother and Child, Lausanne University Hospital, Lausanne, Switzerland
4 shared publications
Latest Publications
- 18 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Long-term Dynamics and Nasopharyngeal Carriage of Pneumococcal Serotypes, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus From 2013 to 2024 in Healthy French Children
Background: Nasopharyngeal carriage of major respiratory bacterial pathogens plays a key role in respiratory infections and transmission. While most carriage studies focus on preschool children, data beyond the age of 6 years remain scarce. This 11-year multicenter study provides a unique overview of carriage dynamics in children up to 15 years old during the Pneumococcal Conjugate Vaccine 13-valent (PCV13) era. Methods: Nasopharyngeal swabs (2013–2024) from 6420 healthy children aged 6 months to 15 years were collected by 87 pediatricians across France. Standard culture identified Streptococcus pneumoniae (Sp), Haemophilus influenzae (Hi), Moraxella catarrhalis (Mc) and Staphylococcus aureus (Sa); pneumococci were serotyped by latex agglutination, and age-specific carriage patterns were analyzed by cross-sectional comparison. Results: Overall pneumococcal carriage was 28.6%, remaining high up to 5 years of age (≈38%) before declining to ~10% in older children. Non-PCV13 serotypes predominated (23B, 11A, 23A, 15B and 35B), but PCV13 serotypes persisted in 10.4% of pneumococcal carriers and 2.9% of children. Serotypes 19A and 19F remained stable across ages, whereas serotype 3 markedly increased, becoming one of the most prevalent in older children. Hi and Mc carriage mirrored pneumococcus patterns in early childhood but declined with age, while Sa carriage rose inversely. Co-carriage of Sp with Hi or Mc was frequent but rare with Sa, independent of age. Conclusions: Sp, Hi and Mc carriage remains high up to 5 years of age and declines quickly afterward, whereas Sa shows an inverse pattern. The persistence of serotypes 19A, 19F and the increasing prevalence of serotype 3 in older children may act as a reservoir fueling invasive pneumococcal infections in adults, underscoring the need for continued surveillance and next-generation vaccine strategies.
- 18 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Long-term Dynamics and Nasopharyngeal Carriage of Pneumococcal Serotypes, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus From 2013 to 2024 in Healthy French Children
Background: Nasopharyngeal carriage of major respiratory bacterial pathogens plays a key role in respiratory infections and transmission. While most carriage studies focus on preschool children, data beyond the age of 6 years remain scarce. This 11-year multicenter study provides a unique overview of carriage dynamics in children up to 15 years old during the Pneumococcal Conjugate Vaccine 13-valent (PCV13) era. Methods: Nasopharyngeal swabs (2013–2024) from 6420 healthy children aged 6 months to 15 years were collected by 87 pediatricians across France. Standard culture identified Streptococcus pneumoniae (Sp), Haemophilus influenzae (Hi), Moraxella catarrhalis (Mc) and Staphylococcus aureus (Sa); pneumococci were serotyped by latex agglutination, and age-specific carriage patterns were analyzed by cross-sectional comparison. Results: Overall pneumococcal carriage was 28.6%, remaining high up to 5 years of age (≈38%) before declining to ~10% in older children. Non-PCV13 serotypes predominated (23B, 11A, 23A, 15B and 35B), but PCV13 serotypes persisted in 10.4% of pneumococcal carriers and 2.9% of children. Serotypes 19A and 19F remained stable across ages, whereas serotype 3 markedly increased, becoming one of the most prevalent in older children. Hi and Mc carriage mirrored pneumococcus patterns in early childhood but declined with age, while Sa carriage rose inversely. Co-carriage of Sp with Hi or Mc was frequent but rare with Sa, independent of age. Conclusions: Sp, Hi and Mc carriage remains high up to 5 years of age and declines quickly afterward, whereas Sa shows an inverse pattern. The persistence of serotypes 19A, 19F and the increasing prevalence of serotype 3 in older children may act as a reservoir fueling invasive pneumococcal infections in adults, underscoring the need for continued surveillance and next-generation vaccine strategies.
- 4 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Respiratory Syncytial Virus Shapes Serotype-Specific Invasive Pneumococcal Disease Dynamics in Children: An Observational Study
Background: Pneumococcal nasopharyngeal colonization is the first step toward invasive pneumococcal disease (IPD). Respiratory syncytial virus (RSV) may trigger IPD, particularly for serotypes with low disease potential. We aimed to analyze the distribution of pneumococcal serotypes among pediatric IPD according to RSV circulation level. Methods: We used data from 3 continuous French surveillance systems on IPD, pneumococcal carriage and RSV infections from 2008 to 2023. Based on the RSV epidemic threshold, we assessed the proportion of each serotype among IPD, depending on “RSV season” and “non-RSV season.” We assessed the correlation between the likelihood of serotype-specific involvement in IPD according to non-RSV season versus RSV season and the estimated disease potential of each serotype. Results: Among 4574 IPD cases, the serotype distribution strongly varied during non-RSV season versus RSV season. The lower the disease potential of serotypes, the more RSV circulation enhanced their involvement in IPD (Rho=0.60, CI95% .28–.80, P = .0012). Conclusions: The role of RSV in triggering IPD strongly varies across pneumococcal serotypes. The impact of RSV-targeted interventions should be evaluated in light of these data.
- 4 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Respiratory Syncytial Virus Shapes Serotype-Specific Invasive Pneumococcal Disease Dynamics in Children: An Observational Study
Background: Pneumococcal nasopharyngeal colonization is the first step toward invasive pneumococcal disease (IPD). Respiratory syncytial virus (RSV) may trigger IPD, particularly for serotypes with low disease potential. We aimed to analyze the distribution of pneumococcal serotypes among pediatric IPD according to RSV circulation level. Methods: We used data from 3 continuous French surveillance systems on IPD, pneumococcal carriage and RSV infections from 2008 to 2023. Based on the RSV epidemic threshold, we assessed the proportion of each serotype among IPD, depending on “RSV season” and “non-RSV season.” We assessed the correlation between the likelihood of serotype-specific involvement in IPD according to non-RSV season versus RSV season and the estimated disease potential of each serotype. Results: Among 4574 IPD cases, the serotype distribution strongly varied during non-RSV season versus RSV season. The lower the disease potential of serotypes, the more RSV circulation enhanced their involvement in IPD (Rho=0.60, CI95% .28–.80, P = .0012). Conclusions: The role of RSV in triggering IPD strongly varies across pneumococcal serotypes. The impact of RSV-targeted interventions should be evaluated in light of these data.
- Open Access
Quantifying the mechanisms of vaccine-induced serotype replacement in Streptococcus pneumoniae using genome-informed modelling
Streptococcus pneumoniae is a colonizer of the child s nasopharynx and a leading cause of invasive pneumococcal disease (IPD). Despite widespread use of pneumococcal conjugate vaccines, recent rebounds in IPD incidence have coincided with serotype replacement. Whether this phenomenon is driven by the replacement of serotypes within lineages or the replacement of the lineages themselves is unclear. Here, we quantified the relative contribution of these two mechanisms to serotype replacement in carriage and their consequences for IPD. We combined nationwide longitudinal surveillance of carriage and IPD in children from 2002 to 2023 with whole-genome sequencing. Observed lineage-specific carriage rates across PCV-related periods were fitted with polynomial logistic regression and compared with two counterfactual scenarios, each isolating one mechanism with: (i) fixed serotype composition within varying lineages and (ii) serotype shifts within fixed lineage carriage rates over time. Carriage dynamics were consistent with an 82% contribution of serotype shifts within persistent lineages. Estimates of serotype-specific IPD incidence derived from this predominant scenario correlated with observed IPD trends. These findings quantify the dominant role of serotype replacement within persistent lineages, disentangling the vaccine-driven adaptive history of S. pneumoniae.
Open AccessQuantifying the mechanisms of vaccine-induced serotype replacement in Streptococcus pneumoniae using genome-informed modelling
Streptococcus pneumoniae is a colonizer of the child s nasopharynx and a leading cause of invasive pneumococcal disease (IPD). Despite widespread use of pneumococcal conjugate vaccines, recent rebounds in IPD incidence have coincided with serotype replacement. Whether this phenomenon is driven by the replacement of serotypes within lineages or the replacement of the lineages themselves is unclear. Here, we quantified the relative contribution of these two mechanisms to serotype replacement in carriage and their consequences for IPD. We combined nationwide longitudinal surveillance of carriage and IPD in children from 2002 to 2023 with whole-genome sequencing. Observed lineage-specific carriage rates across PCV-related periods were fitted with polynomial logistic regression and compared with two counterfactual scenarios, each isolating one mechanism with: (i) fixed serotype composition within varying lineages and (ii) serotype shifts within fixed lineage carriage rates over time. Carriage dynamics were consistent with an 82% contribution of serotype shifts within persistent lineages. Estimates of serotype-specific IPD incidence derived from this predominant scenario correlated with observed IPD trends. These findings quantify the dominant role of serotype replacement within persistent lineages, disentangling the vaccine-driven adaptive history of S. pneumoniae.
- 4 February 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (3)
Epidemiology and Characteristics of Bacterial Meningitis of Children with Cerebrospinal Fluid Leakage or Cochlear Implant
Cerebrospinal (CSF) fluid leakage is a recognized risk factor for bacterial meningitis. Few data are published concerning bacterial meningitis in children with cerebrospinal fluid leakage, and the impact of 13 valent pneumococcal conjugate vaccination (PCV13) in this population is not well known. The aim of this study was to describe the epidemiology of bacterial meningitis in children with known CSF leakage. Methods: Among all bacterial meningitis in children > 3 months old, we analyzed those with known CSF leakage (meningeal breach and/or cochlear implant resulting in meningitis) in a nationwide prospective cohort between 2001 and 2024 in France, with 227 pediatric wards and 168 microbiology departments. Of 5,879 cases of bacterial meningitis in children over 3 months old, 251 (4.3%) were associated with known CSF leakage. In this population, Streptococcus pneumoniae (78.9%) was the most frequent bacteria involved, followed by Haemophilus influenzae (10%), mainly non typeable strains. Two cases of Neisseria meningitidis were recorded and only in children with cochlear implant. For children with known CSF leakage, in late PCV13 period, PCV13, PCV15, PCV20, PCV21 and PPSV23 serotypes accounted for 14%, 16.3%, 37.2%, 79.1% and 27.9%, respectively. In this population, serotype 23B was the most frequent (18.6%), followed by 11A (9.3%), 15A (9.3%), 19F (7%), 3 (4.7%) and 19A (2.3%). Bacterial meningitis in children with known CSF leakage is largely due to pneumococci and now mainly due to serotypes not included in PCV13. Only two cases of meningococcal meningitis were found and only for children with cochlear implant.
- 4 February 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (3)
Epidemiology and Characteristics of Bacterial Meningitis of Children with Cerebrospinal Fluid Leakage or Cochlear Implant
Cerebrospinal (CSF) fluid leakage is a recognized risk factor for bacterial meningitis. Few data are published concerning bacterial meningitis in children with cerebrospinal fluid leakage, and the impact of 13 valent pneumococcal conjugate vaccination (PCV13) in this population is not well known. The aim of this study was to describe the epidemiology of bacterial meningitis in children with known CSF leakage. Methods: Among all bacterial meningitis in children > 3 months old, we analyzed those with known CSF leakage (meningeal breach and/or cochlear implant resulting in meningitis) in a nationwide prospective cohort between 2001 and 2024 in France, with 227 pediatric wards and 168 microbiology departments. Of 5,879 cases of bacterial meningitis in children over 3 months old, 251 (4.3%) were associated with known CSF leakage. In this population, Streptococcus pneumoniae (78.9%) was the most frequent bacteria involved, followed by Haemophilus influenzae (10%), mainly non typeable strains. Two cases of Neisseria meningitidis were recorded and only in children with cochlear implant. For children with known CSF leakage, in late PCV13 period, PCV13, PCV15, PCV20, PCV21 and PPSV23 serotypes accounted for 14%, 16.3%, 37.2%, 79.1% and 27.9%, respectively. In this population, serotype 23B was the most frequent (18.6%), followed by 11A (9.3%), 15A (9.3%), 19F (7%), 3 (4.7%) and 19A (2.3%). Bacterial meningitis in children with known CSF leakage is largely due to pneumococci and now mainly due to serotypes not included in PCV13. Only two cases of meningococcal meningitis were found and only for children with cochlear implant.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in ISME Communications
- Vol. 6 (1)
Quantifying the mechanisms of vaccine-induced serotype replacement in Streptococcus pneumoniae using genome-informed modelling
Streptococcus pneumoniae is a colonizer of the child’s nasopharynx and a leading cause of invasive pneumococcal disease (IPD). Despite widespread use of pneumococcal conjugate vaccines (PCV), recent rebounds in IPD incidence have coincided with serotype replacement. The relative contribution of the replacement of serotypes within lineages and the replacement of the lineages themselves to this phenomenon is unclear. Yet these two evolutionary mechanisms may affect differently the fitness of S. pneumoniae and have distinct consequences on vaccination strategies. Here, we quantified the relative contribution of these two mechanisms to serotype replacement in carriage and their consequences for IPD. We combined nationwide longitudinal surveillance of carriage in children with acute otitis media and IPD in children from 2002 to 2023 with whole-genome sequencing. Observed lineage-specific carriage rates across PCV-related periods were fitted with polynomial logistic regression and compared with two counterfactual scenarios, each isolating one mechanism: (i) fixed serotype composition within varying lineages and (ii) serotype shifts within fixed lineage carriage rates over time. Carriage dynamics were consistent with an 82% contribution of serotype shifts within persistent lineages. Estimates of serotype-specific IPD incidence derived from this predominant scenario correlated with observed IPD trends. These findings quantify the dominant role of serotype replacement within persistent lineages, disentangling the vaccine-driven adaptive history of S. pneumoniae.
- 14 January 2026
- Published by Oxford University Press (OUP) in ISME Communications
- Vol. 6 (1)
Open AccessQuantifying the mechanisms of vaccine-induced serotype replacement in Streptococcus pneumoniae using genome-informed modelling
Streptococcus pneumoniae is a colonizer of the child’s nasopharynx and a leading cause of invasive pneumococcal disease (IPD). Despite widespread use of pneumococcal conjugate vaccines (PCV), recent rebounds in IPD incidence have coincided with serotype replacement. The relative contribution of the replacement of serotypes within lineages and the replacement of the lineages themselves to this phenomenon is unclear. Yet these two evolutionary mechanisms may affect differently the fitness of S. pneumoniae and have distinct consequences on vaccination strategies. Here, we quantified the relative contribution of these two mechanisms to serotype replacement in carriage and their consequences for IPD. We combined nationwide longitudinal surveillance of carriage in children with acute otitis media and IPD in children from 2002 to 2023 with whole-genome sequencing. Observed lineage-specific carriage rates across PCV-related periods were fitted with polynomial logistic regression and compared with two counterfactual scenarios, each isolating one mechanism: (i) fixed serotype composition within varying lineages and (ii) serotype shifts within fixed lineage carriage rates over time. Carriage dynamics were consistent with an 82% contribution of serotype shifts within persistent lineages. Estimates of serotype-specific IPD incidence derived from this predominant scenario correlated with observed IPD trends. These findings quantify the dominant role of serotype replacement within persistent lineages, disentangling the vaccine-driven adaptive history of S. pneumoniae.
- Open Access
- 21 January 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (5) , e184-e186
Similarities and Differences Between Countries When Estimating the Effect of Higher-valency Pneumococcal Conjugate Vaccines on Colonization and Acute Otitis Media
- 21 January 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (5) , e184-e186
Open AccessSimilarities and Differences Between Countries When Estimating the Effect of Higher-valency Pneumococcal Conjugate Vaccines on Colonization and Acute Otitis Media
- Open Access
- 4 January 2025
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 35 (1) , 1-8
Description and characterization of pneumococcal community acquired pneumonia (CAP) among radiologically confirmed CAP in outpatients
Streptococcus pneumoniae (SP) remains an important cause of community acquired pneumonia (CAP). We aimed to describe the prevalence and characteristics of outpatients with radiologically confirmed pneumococcal CAP. Between November 2017 and December 2019, a French network of general practitioners enrolled CAP-suspected adults, with ≥1 clinical signs of infection and ≥1 signs of pulmonary localization in an observational study. Pneumococcal CAP was defined by the combination of a chest X-ray (CXR) compatible with CAP and SP detection by any of four microbiological tests (blood culture, sputum culture, pneumococcal urinary antigen test [BinaxNow®] and serotype-specific multiplex urinary antigen detection test [Pfizer Inc®]. To identify other pathogens, next to cultures, nasopharyngeal multiplex PCR was performed. Three hundred and forty-eight patients were included, of whom 144 had a positive CXR, 135/144 (93.8%) had not received antibiotics prior to inclusion, 21/144 (14.6%) had ≥1 positive microbiological test for SP, and 66/144 (45.8%) were negative for all four microbiological tests and were considered as non-pneumococcal CAP. Pneumococcal serotypes were identified for 12 patients. This study assessing the prevalence of SP among CAP outpatients using comprehensive microbiologic testing shows that SP is still the most frequently identified microorganism.
- 4 January 2025
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 35 (1) , 1-8
Open AccessDescription and characterization of pneumococcal community acquired pneumonia (CAP) among radiologically confirmed CAP in outpatients
Streptococcus pneumoniae (SP) remains an important cause of community acquired pneumonia (CAP). We aimed to describe the prevalence and characteristics of outpatients with radiologically confirmed pneumococcal CAP. Between November 2017 and December 2019, a French network of general practitioners enrolled CAP-suspected adults, with ≥1 clinical signs of infection and ≥1 signs of pulmonary localization in an observational study. Pneumococcal CAP was defined by the combination of a chest X-ray (CXR) compatible with CAP and SP detection by any of four microbiological tests (blood culture, sputum culture, pneumococcal urinary antigen test [BinaxNow®] and serotype-specific multiplex urinary antigen detection test [Pfizer Inc®]. To identify other pathogens, next to cultures, nasopharyngeal multiplex PCR was performed. Three hundred and forty-eight patients were included, of whom 144 had a positive CXR, 135/144 (93.8%) had not received antibiotics prior to inclusion, 21/144 (14.6%) had ≥1 positive microbiological test for SP, and 66/144 (45.8%) were negative for all four microbiological tests and were considered as non-pneumococcal CAP. Pneumococcal serotypes were identified for 12 patients. This study assessing the prevalence of SP among CAP outpatients using comprehensive microbiologic testing shows that SP is still the most frequently identified microorganism.
- Open Access
- 13 June 2024
- Published by Elsevier in Infectious Diseases Now
- Vol. 54 (5) , 104937
The latest news in France before distribution of third-generation pneumococcal conjugate vaccines
- 13 June 2024
- Published by Elsevier in Infectious Diseases Now
- Vol. 54 (5) , 104937
Open AccessThe latest news in France before distribution of third-generation pneumococcal conjugate vaccines
- Open Access
- 13 November 2023
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (1) , 74-83
Vaccine-preventable Pediatric Acute Bacterial Meningitis in France: A Time Series Analysis of a 19-Year Prospective National Surveillance Network
Background: In France, vaccination has been implemented against Hi serotype b (Hib), pneumococcus with pneumococcal conjugate vaccines (PCV), and Neisseria meningitidis serogroup C (MenC). These interventions with different coverage and uptake have disrupted the epidemiology of vaccine-preventable acute bacterial meningitis (ABM). Methods: We analyzed data from a French prospective surveillance network of ABM in children ≤15 years old enrolled by 259 pediatric wards (estimated national coverage: 61%). From 2001 to 2020, the effect of vaccine implementation was estimated with segmented linear regression. Results: We analyzed 7,186 cases, mainly due to meningococcus (35.0%), pneumococcus (29.8%), and Hi (3.7%). MenC ABM incidence decreased (−0.12%/month, 95% CI: −0.17 to −0.07, P < 0.001) with no change for the overall meningococcal ABM when comparing the pre-MenC vaccination and the post-MenC vaccination trends. Despite a decreasing MenB ABM incidence without a vaccination program (−0.43%/month, 95% CI: −0.53 to −0.34, P < 0.001), 68.3% of meningococcal ABM involved MenB. No change in pneumococcal ABM incidence was observed after the PCV7 recommendation. By contrast, this incidence significantly decreased after the switch to PCV13 (−0.9%/month, 95% CI: −1.6 to −0.2%, P = 0.01). After May 2014, a rebound occurred (0.5%/month, 95% CI: 0.3–0.8%, P < 0.001), with 89.5% of non-PCV13 vaccine serotypes. Hib ABM incidence increased after June 2017. Conclusions: PCV7 and MenC vaccine introduction in France, with slow vaccine uptake and low coverage, had no to little impact as compared to the switch from PCV7 to PCV13, which occurred when coverage was optimal. Our data suggest that MenB and next-generation PCVs could prevent a large part of the ABM incidence in France.
- 13 November 2023
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (1) , 74-83
Open AccessVaccine-preventable Pediatric Acute Bacterial Meningitis in France: A Time Series Analysis of a 19-Year Prospective National Surveillance Network
Background: In France, vaccination has been implemented against Hi serotype b (Hib), pneumococcus with pneumococcal conjugate vaccines (PCV), and Neisseria meningitidis serogroup C (MenC). These interventions with different coverage and uptake have disrupted the epidemiology of vaccine-preventable acute bacterial meningitis (ABM). Methods: We analyzed data from a French prospective surveillance network of ABM in children ≤15 years old enrolled by 259 pediatric wards (estimated national coverage: 61%). From 2001 to 2020, the effect of vaccine implementation was estimated with segmented linear regression. Results: We analyzed 7,186 cases, mainly due to meningococcus (35.0%), pneumococcus (29.8%), and Hi (3.7%). MenC ABM incidence decreased (−0.12%/month, 95% CI: −0.17 to −0.07, P < 0.001) with no change for the overall meningococcal ABM when comparing the pre-MenC vaccination and the post-MenC vaccination trends. Despite a decreasing MenB ABM incidence without a vaccination program (−0.43%/month, 95% CI: −0.53 to −0.34, P < 0.001), 68.3% of meningococcal ABM involved MenB. No change in pneumococcal ABM incidence was observed after the PCV7 recommendation. By contrast, this incidence significantly decreased after the switch to PCV13 (−0.9%/month, 95% CI: −1.6 to −0.2%, P = 0.01). After May 2014, a rebound occurred (0.5%/month, 95% CI: 0.3–0.8%, P < 0.001), with 89.5% of non-PCV13 vaccine serotypes. Hib ABM incidence increased after June 2017. Conclusions: PCV7 and MenC vaccine introduction in France, with slow vaccine uptake and low coverage, had no to little impact as compared to the switch from PCV7 to PCV13, which occurred when coverage was optimal. Our data suggest that MenB and next-generation PCVs could prevent a large part of the ABM incidence in France.
- Open Access
- 8 November 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (11) , 1605
Antibiotic Resistance of Haemophilus influenzae in Nasopharyngeal Carriage of Children with Acute Otitis Media and in Middle Ear Fluid from Otorrhea
Haemophilus influenzae (Hi) is one of the leading bacteria implicated in childhood acute otitis media (AOM). Recent concerns have been raised about the emergence of Hi-resistant strains. We aimed to analyze the evolution of β-lactam resistance to Hi among strains isolated from nasopharyngeal carriage in children with AOM and in mild ear fluid (MEF) after the spontaneous perforation of the tympanic membrane (SPTM) in France. In this national ambulatory-based cohort study over 16 years, we analyzed the rate of Hi nasopharyngeal carriage and the proportion of β-lactam-resistant Hi strains over time using a segmented linear regression model. Among the 13,865 children (median [IQR] age, 12.7 [9.3–17.3] months; 7400 [53.4%] male) with AOM included from November 2006 to July 2022, Hi was isolated in 7311 (52.7%) children by nasopharyngeal sampling. The proportion of β-lactamase-producing and β-lactamase-negative, ampicillin-resistant (BLNAR) Hi strains in nasopharyngeal carriage remained stable during the study period. Among the 783 children (median [IQR] age, 20 [12.3–37.8] months; 409 [52.2%] male) with SPTM included from October 2015 to July 2022, Hi was isolated in 177 (22.6%) cases by MEF sampling. The proportions of β-lactamase-producing and BLNAR Hi strains did not significantly differ between nasopharyngeal (17.6% and 8.8%, respectively) and MEF (12.6% and 7.4%) samples. Accordingly, amoxicillin remains a valid recommendation as the first-line drug for AOM in France.
- 8 November 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (11) , 1605
Open AccessAntibiotic Resistance of Haemophilus influenzae in Nasopharyngeal Carriage of Children with Acute Otitis Media and in Middle Ear Fluid from Otorrhea
Haemophilus influenzae (Hi) is one of the leading bacteria implicated in childhood acute otitis media (AOM). Recent concerns have been raised about the emergence of Hi-resistant strains. We aimed to analyze the evolution of β-lactam resistance to Hi among strains isolated from nasopharyngeal carriage in children with AOM and in mild ear fluid (MEF) after the spontaneous perforation of the tympanic membrane (SPTM) in France. In this national ambulatory-based cohort study over 16 years, we analyzed the rate of Hi nasopharyngeal carriage and the proportion of β-lactam-resistant Hi strains over time using a segmented linear regression model. Among the 13,865 children (median [IQR] age, 12.7 [9.3–17.3] months; 7400 [53.4%] male) with AOM included from November 2006 to July 2022, Hi was isolated in 7311 (52.7%) children by nasopharyngeal sampling. The proportion of β-lactamase-producing and β-lactamase-negative, ampicillin-resistant (BLNAR) Hi strains in nasopharyngeal carriage remained stable during the study period. Among the 783 children (median [IQR] age, 20 [12.3–37.8] months; 409 [52.2%] male) with SPTM included from October 2015 to July 2022, Hi was isolated in 177 (22.6%) cases by MEF sampling. The proportions of β-lactamase-producing and BLNAR Hi strains did not significantly differ between nasopharyngeal (17.6% and 8.8%, respectively) and MEF (12.6% and 7.4%) samples. Accordingly, amoxicillin remains a valid recommendation as the first-line drug for AOM in France.